Proactive Investors
04 Nov 2025, 21:25 UTC · 46w ago
Verdict
Headline takes no side. We score LSTA +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Preclinical data indicates that Lisata Therapeutics' certepetide can enhance the tumor penetration and effectiveness of antibody-drug conjugates (ADCs).
So whatPositive efficacy data for a lead molecule in a high-growth therapeutic category (ADCs) typically drives significant valuation increases for small-cap biotech.
More positive than 93% of claims this week
Lisata has established a licensing partnership with Catalent to integrate certepetide into the SMARTag ADC platform.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 79% of claims this week
Lisata Therapeutics' shares rose 8% in after-hours trading following the presentation of the preclinical results.
More positive than 66% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company reported promising preclinical results for certepetide and saw an 8% increase in after-hours share price.
More positive than 75% of relationship scores this week
[mutual] Lisata Therapeutics has a licensing partnership with Catalent to use certepetide with the SMARTag platform.
More positive than 34% of relationship scores this week
[a_to_b] Lisata licensed certepetide and its analogs to Catalent for use in its ADC platform.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
9h ago
−36.0%
Price is moving against the score
$1.58 vs $2.47 close before publication (Nov 4) · not market-adjusted
LSTA chart →
